[0001] The present invention relates in general to the immunology field and specifically
to anti-idiotype monoclonal antibodies or fragments thereof, which specifically react
to human antibodies capable of binding to the human acquired immunodeficiency virus
(HIV) gp120 protein and capable of inducing an anti-gp120 response when administered
to an animal, including a human being.
BACKGROUND OF THE INVENTION
[0002] Over the course of time, the impact of HIV infection has reached worldwide proportions.
Throughout the world it is estimated that there are approximately 40 million infected
people, with a constantly growing incidence of new infections certified in 5 million
new cases per year (
UNAIDS - AIDS Epidemic Update - 2005). The impossibility of carrying out control mechanisms for the infection, or their
ineffectiveness, has already determined horrifying pictures in certain areas of the
globe. For instance, in certain regions of sub-Saharan Africa (the region of the world
most affected by the pandemic) it is estimated that more than 50% of working-age subjects
are seropositive, with obvious repercussions on the economies of this area of the
world already devastated in any case. But a similar course is also occurring in areas
that are experiencing periods of impressive economic growth, such as the Indian subcontinent
and South-East Asia. In these areas the number of seropositives is close to 10 million,
with an annual exponential increase of new cases (
UNAIDS - AIDS Epidemic Update - 2005).
The antiretroviral therapy, where available, has improved the infected subjects' life
expectancy. However it is linked to a series of adverse factors that within a few
years could reduce its positive impact. First of all, today's available therapies
are not curative; in other words, treated subjects fail to eliminate the virus completely,
but remain infected and thus exposed to the risk of developing the severe clinical
forms of infection (evident AIDS), and anyway of transmitting the infection to other
people. Furthermore, available drugs are burdened with very serious side effects.
This causes patients' low compliance with the therapy itself. Low compliance, along
with the high molecular adaptability of the virus and other factors, has favoured
the onset and spread of completely drug-resistant HIV isolates. Furthermore, the high
cost of the therapy makes its use absolutely unlikely on a large scale in the world's
depressed areas that, as mentioned above, represent the true explosive reservoir of
infection at global level.
[0003] Overall, the above described factors make the necessity of working out alternative
or, at worst complementary, strategies to the therapy of overriding importance: in
the scope of HIV infection control, the development of an effective vaccine approach
would certainly have a priority role.
[0004] Unfortunately, HIV infection is still nowadays an open challenge and difficult to
solve by the scientific community. In fact, traditional vaccine approaches, based
on administration of viral particles that are unable to infect but able to stimulate
the immune system, have been demonstrated as completely ineffective towards a virus
that uses molecular polymorphism, i.e. the ability to mutate in order to escape the
immune response, as its own winning weapon (
McMichael J., (2006) Annu. Rev. Immunol. 24: 227-55).
[0005] In the following description, after having briefly illustrated the main immunological
mechanisms stimulated by HIV, the various main vaccine strategies followed up to now
will be synthetically reviewed, dwelling in particular on the strategy followed in
the approach underlying the invention which is the subject of the present patent application,
i.e. the attainment and administration of anti-idiotype mimotopes.
The immune response directed against HIV
[0006] The natural history of HIV infection witnesses uncontrolled replication of the virus
within early weeks after the infection, with viremia levels that often exceed values
of 10
7 virus particles per ml of plasma within the first 21 days. This first stage is followed
by another characterized by a sudden decrease in viremic levels, due to activation
of specific response mechanisms, represented by cytotoxic CD8+ T cells and production
of neutralising antibodies. This stage demonstrates how the immune system, once stimulated,
is able to at least partially control the infection. However, the main concern is
represented by, as mentioned in the previous section, the hypervariability of certain
viral proteins, which enable the virus to overcome the stimulated defences and thus
resume replication in an uncontrolled manner. In the case of HIV infection, the immune
system is thus continuously called upon to run after the virus variability: however,
the natural history of the infection demonstrates that the immune system results constantly
defeated in this chase.
[0007] The main object of an effective prophylactic vaccine would then be to present the
virus, since the first contact, with an immune response able to block it and thus
prevent its uncontrolled propagation in the organism.
[0008] Surface HIV proteins (gp120 and gp41), that make target cell infection possible,
represent the main targets of the immune response and in particular of humoral-type
immune response. Antibodies generated in the course of a natural infection however
assure a protection that is limited to the virus that has stimulated such a response.
In other words, those very antibodies will not be able to protect the patient who
produced them from new viral variants that will develop, and (the most important fact
from the vaccine point of view) all the more so would not prove protective for other
patients infected by other HIV variants.
[0009] The study of HIV-induced antibody response has however evidenced a possible role
played by antibody clones with broad neutralising activity against a large panel of
virus isolates (
Pantophlet R. and Burton D.R., (2006) Annu. Rev. Immunol. 24: 739-769). Still, only a few patients are able to produce antibodies with similar features,
that will allow them to control the infection for a much longer period, slowing down
progression towards evident AIDS (
Braibant M. et al., (2006) AIDS. 20: 1923-30). These patients are defined by the scientific community as long-term non-progressors
(LTNP) and certainly represent an example of anti-HIV immune response to be studied
for the development of an effective vaccine.
[0010] In the light of the collected data, the scientific community has at this point almost
universally recognized that an effective prophylactic or therapeutic vaccine should
be able to stimulate an adequate antibody response, analogous to that described in
LTNP patients. The main target of a potentially effective humoral response is represented
by, as previously mentioned, the two surface glycoproteins (gp120 and gp41) that,
in the form of trimers, compose the spikes that enable the virus to bind and penetrate
within target cells. However, in particular, conserved key epitopes, and thus common
to the different virus isolates, should be detected within these proteins. Laboratory
and clinical experimental data have actually proved that the broad neutralising activity
response is indeed directed against these epitopes (
Braibant M. et al., (2006) AIDS. 20: 1923-30). The scientific community unanimously recognizes that the presence of antibodies
with similar features at the time of the first contact with the virus most probably
would be able to neutralise the infection, attaining what not even the most effective
therapeutic protocol has succeeded in obtaining yet, i.e. complete virus clearance
(
Pantophlet R. and Burton D.R., (2006) Annu. Rev. Immunol. 24: 739-769).
Viral escape mechanisms
[0011] The selective pressure exerted by cellular and humoral immune response against HIV
virus has been studied in great depth in literature, although its effects on the progression
of immunological deficiency and hence on clinics are not clear. The selective pressure
effected by neutralising antibodies is indeed easily observable both
in vitro and
in vivo since the early infection stages. In fact, the virus escapes through a series of
mutations that make the usually generated non-broad range neutralising antibodies
useless. Such mutations, that sometimes involve a single amino acid residue, typically
implicate the surface glycoproteins and in particular the so-called gp120 protein
V (variable) regions. Therefore, it is easily understandable that this key antigen's
sequence variability is one of the main reasons for the inability of the antibodies
generated in the course of natural infection to completely block the virus. In this
context, the molecular reasons of the failure of all "classical" attempts at obtaining
a protective response by immunizing subjects with whole virus particles or recombinant
gp120 are likewise easily understandable (
Pantophlet R. and Burton D.R., (2006) Annu. Rev. Immunol. 24: 739-769).
[0012] However, HIV defence mechanisms are not limited to the strategy, already effective
in itself, of hypervariability. Structural studies of the virus have in fact revealed
how HIV exploits its own hypervariable regions in order to hide key epitopes from
the immune system too, such as the CD4-binding site and the so-called gp120 coreceptor-binding
site, i.e. the protein portions that physically bind the target cell receptor and
coreceptors at the time of infection. In other words, the virus would only expose
these key regions at the time of direct interaction with the target cell, thus limiting
their exposure to the immune system.
[0013] Also, HIV has developed another strategy of hiding gp120 most important epitopes:
50% of the molecule is actually covered with carbohydrates, that make the protein
surface practically "invisible" to the immune system.
In vivo the virus can also modify the positions of this glucidic coating, thus leading to
the hypothesis of a dynamic evolution model, the so-called glycan shield. HIV would
actually be able to modulate glycosilation, continuously adapting to the kind of immune
response that from time to time it has to contrast. Therefore, the ability of escaping
the immune response is not a widespread phenomenon, an inherent feature common to
all virus particles, but a specific and continuous adaptation to the neutralising
antibody response that is stimulated each time.
gp120 as a potential vaccine target
[0014] As disclosed in the two previous sections, gp120 represents the main target of HIV
virus-neutralising immune response. However, in the previous sections, the molecular
reasons why classical vaccine approaches, even though contemplating the use of an
antigen so important to the virus, did not lead to positive results have been pointed
out. In particular, the use of inactivated whole virus particles, or of gp120 recombinant
monomeric forms, leads to stimulation of an immune response merely limited to the
virus used in the vaccine protocol, or from which the recombinant protein had been
obtained. For instance, the stimulated response turned out to be limited to HIV isolates
adapted in laboratory to grow on immortalized T cell line cultures. Instead, no antiviral
effect was seen against "primary" virus isolates, i.e. isolates directly derived from
infected patients.
[0015] The failure of these approaches has led to investigation of possible alternative
routes that will be briefly disclosed in this section of the specification, and can
be synthetically divided into two groups.
a) Development of gp120 trimeric preparations which represent the protein structure
displayed on HIV spikes better.
[0016] This approach relies on administration of gp120, no longer in monomeric form but
in heterotrimeric form, in association with the other viral surface glycoprotein,
the gp41 protein. The principle at the root of this strategy is based on the observation
of the different antigenic features of monomeric gp120 compared to the trimeric forms
(
Pantophlet R. and Burton D.R., (2006) Annu. Rev. Immunol. 24: 739-769). However, the first data collected from approaches regarding this strategy have
revealed a series of problems tightly connected with each other, both from the technical
point of view and from the point of view regarding the effectiveness of the approach
itself. From the technical viewpoint, the main obstacle to be overcome consists indeed
in the ability of obtaining stable heterotrimeric forms that are best able to mime
the organisation of the viral envelope spikes. On HIV surface, in fact, gp120-gp41
interactions are mediated by non-covalent interactions essential in order to give
the overall structure of the spike the indispensable structural adaptability that
characterizes its function. In laboratory, it has proved particularly difficult to
obtain such molecules, which on one hand should be stable enough not to dissociate
into single monomers, and on the other hand should however be able to display critical
portions of the proteins, and particularly of gp120. It has therefore been necessary
to adopt a series of technical stratagems in order to stabilize the trimers (mutation
into the original polyprotein cleavage sites, insertion of cysteine residues into
unimportant portions of the structure), or to display them onto structures as similar
as possible to the viral envelope (inclusion into proteoliposomes, expression on virus-like
particles). However, none of the approaches followed have allowed for completely solving
the trimer stabilisation and purification problems, nor have they led to definitely
superior results compared to those obtained with monomeric forms of gp120, in terms
of efficacy and especially of the extent of the neutralising activity. The results
obtained with approaches contemplating the use of gp120 recombinant forms mutated
in order to make key portions of the protein more available to the immune system were
similarly unsatisfactory.
b) Development of innovative epitope-based vaccines, i.e. based on exposure to the
immune system of conserved, therefore potentially protective, portions of gp120.
[0017] This group is connected with the anti-idiotype mimotope strategy, on which the invention
illustrated in the present patent application is also based.
[0018] The main problem with all the above illustrated strategies concerns the inability
to stimulate, in addition to a type-specific neutralising response, a broad range
neutralising response. The so-called epitope-based approaches must be considered within
the sphere of the attempts to reduce the type-specific response and enhance the cross-neutralising
one.
[0019] To better understand the strategies connected with this group, it is useful to make
a brief reference to the gp120 antigen structure. Based on comparative sequence analysis,
the study of gp120 reveals, as regards the glycoprotein, 5 conserved (C1-C5) and 5
variable (V1-V5) segments. Further studies have demonstrated that the C1 and C5 regions
are probably engaged in the contact with gp41, as it has been evidenced that antibodies
directed against this region only recognize monomeric forms of gp120, not the trimeric
ones. Instead, certain portions of the C2, C3 and C4 regions possibly form a hidden
and relatively hydrophobic nucleus within the gp120 molecule, probably involved in
CD4 receptor recognition. Unlike conserved regions, the variable regions (particularly
V1, V2 and V3) are well exposed and accessible on the protein.
[0020] The epitope-based approaches in fact attempt to exploit gp120 structural features
in order to obtain molecules that are able to target the immune response exclusively,
or predominantly, to its key epitopes. In this context, one strategy has been to use
gp120 monomers, from which the V1, V2 and V3 regions had been removed, in order to
expose the conserved CD4-binding portions to the immune system. A similar approach
has not yet given satisfactory results, also because the removal of such large portions
from the protein has inevitable effects on its whole conformation and hence on the
CD4-binding portion that might lose its own distinctive features.
[0021] Another possible strategy is to exploit, to the immune system's advantage, one of
the HIV escape mechanisms previously disclosed, i.e. hyperglycosylation of gp120 portions.
In this connection, artificially glycosylated gp120s have been obtained in laboratory,
in order to hide non-protective sites and target the response exclusively to the protein's
important portions. However, the results obtained with this approach have been unsatisfactory,
in as much as this strategy, although leading to a reduction in the immune response
directed against non-conserved portions of the molecule, has not been able to cause
an extensive response to gp120 crucial portions.
[0022] At this point, it is useful to recall that, in some rare cases and in very low titres,
in the course of certain natural infections, antibodies capable of neutralising a
broad range of viral isolates are generated. Such antibodies (extremely rare and precious
from the scientific point of view) thus represent an ideal template for an extremely
targeted epitope-based approach. Exploiting the idiotype of these molecules (i.e.
the antibody portion that specifically recognizes and binds the antigen), it is possible,
by using a reverse vaccinology approach, to obtain other (anti-idiotype) antibody
molecules which are specifically directed against the idiotype of broad range neutralising
antibodies, and thus able to mime the key epitopes that they recognize. In other words,
well designed anti-idiotype antibodies may represent an artificial antigen unrivalled
in laboratory, as they are able to expose just the neutralising antibody-recognized
key epitope to the immune system.
[0023] The analysis of prior scientific and patent literature has allowed for pointing out
that anti-idiotype-based strategies have already been applied to HIV infection.
[0024] However, as far as the inventors know, the majority of prior literature relates to
anti-idiotype antibodies obtained using, as the cloning template, non-human derived,
especially mouse-derived, antibody molecules, i.e. antibodies obtained immunizing
laboratory mice with recombinant gp120. As it has been many times scientifically demonstrated
that one identical epitope may be able to stimulate a specific antibody response in
an experimental animal but not in human beings, the choice of using non-human derived
polyclonal preparations or monoclonal antibodies as the template for obtaining anti-idiotype
antibodies makes the attainment of anti-idiotype antibodies useful for vaccine purposes
in man uncertain; i.e. it is uncertain that they would be capable of effectively miming
fundamental gp120 antigen portions recognized by the human immune system and of accordingly
being able to stimulate an effective immune response in human beings.
Human-derived template antibodies
[0025] However, a few prior documents describe human monoclonal antibodies with neutralising
activity, which in some cases are proposed as the template for obtaining of anti-idiotype
molecules. The majority of such prior documents, however, do not describe in practical
terms the production of anti-idiotype molecules, nor their properties and applications.
[0026] The inventors are acquainted with only one prior patent document in which the achievement
of anti-idiotype antibodies starting from human-derived template antibodies is concretely
disclosed. It is International Patent Application
WO 92/15885, published on September 17, 1992. This patent application discloses a method for selection of anti-idiotype monoclonal
antibodies useful for vaccine purposes for the prophylactic or therapeutic treatment
of HIV infections. In brief, this method contemplates the attainment of anti-idiotype
monoclonal antibodies (G1-Ab2s) using as the template a polyclonal preparation of
whole anti-gp120 human Igs (Ab1s), the subsequent selection of a subset of anti-idiotype
monoclonal antibodies (G2-Ab2s) characterized by the ability to react with
in vitro multiple HIV strain-neutralising anti-gp120 antibodies, and the selection of a further
subset of anti-idiotype monoclonal antibodies (G3-Ab2s) capable of generating, in
a primate host, an anti-anti-idiotype antibody (Ab3) response, which antibodies react
with the gp120 antigen and have HIV neutralising properties.
[0027] The procedure described in the
WO 92/15885 application shows several disadvantages. First of all, by using whole immunoglobulins
as the template, a panel of anti-immunoglobulin monoclonal antibodies are obtained
which are mostly directed towards useless portions of the template immunoglobulins,
i.e. the portions outside the idiotype, and which for the most part are therefore
not true anti-idiotypes. Furthermore, the neutralising response achieved in primates
disclosed in this patent application is weak and requires prior purification of the
antibodies used in the immunization. It can thus be concluded that the antibodies
obtained with the
WO 92/15885 method, besides not being sufficiently specific to the useful portion of the anti-gp120
immunoglobulins (the idiotype), are not able to evoke a strong neutralising immune
response (low antibody titres) and thus are not particularly promising as vaccines.
[0028] A further piece of prior art is
US 2005/221298 A, which disclosed the monoclonal antibody designated as 1F7 which is capable of reacting
with human anti-gp120 antibodies and of inhibiting the proliferation of B cell clones
producing antibodies which are no longer affective against HIV-1.
OBJECT OF THE INVENTION
[0029] The object of the present invention is to deal with the above illustrated problems
of the prior art.
[0030] More particularly, one object of the invention is to provide anti-immunoglobulin
monoclonal antibodies, or antibody fragments thereof, that are able to immunologically
bind to the idiotype of human anti-HIV gp120 antibodies and which can therefore be
defined as "anti-idiotype antibodies".
[0031] Another object of the invention is to provide anti-idiotype monoclonal antibodies,
as hereinabove defined, or antibody fragments thereof, that are able to inhibit the
immunological binding between the gp120 antigen and human anti-gp120 antibodies.
[0032] Another object of the invention is to provide anti-idiotype monoclonal antibodies,
as hereinabove defined, or fragments thereof, that are able to evoke a rapid and strong
anti-anti-idiotype antibody immune response directed against HIV, when administered
to an animal, including a human being.
[0033] Another object of the invention is to provide a method for the preparation of anti-idiotype
monoclonal antibodies, as hereinabove defined, or fragments thereof, allowing for
obtaining a panel of monoclonal antibodies that are specifically directed towards
the useful portion of the human anti-gp120 immunoglobulins used as the template, i.e.
their idiotype, and which are able to neutralise the HIV virus.
DESCRIPTION OF THE INVENTION
[0034] These and other objects are achieved by the anti-idiotype antibodies, their nucleotide
and amino acid sequences and the preparation method thereof, as defined in the appended
claims. The claims form an integral part of the description.
[0035] More particularly, the invention relates to a method for the preparation of suitable
anti-idiotype monoclonal antibodies for the prophylactic or therapeutic treatment
of HIV infection or diseases related thereto, which comprises a first step wherein
a preparation of human polyclonal antibodies directed towards the HIV gp120 antigen
(and therefore further referred to as "anti-gp120 antibodies") is provided, which
preparation will subsequently be used as the template for the preparation of anti-idiotype
antibodies.
[0036] It is important that the preparation of human polyclonal anti-gp120 antibodies to
be subsequently used as the template is pre-selected for its broad range neutralising
activity against HIV. The pre-selection is preferably carried out by choosing, as
the antibody source, sera from HIV-positive patients clinically characterized by a
slow progression of the disease (long-term non-progressors). Such patients are chosen
by following the extremely stringent clinical-virological criteria illustrated in
the experimental section of the description. The observance of such criteria allows
for obtaining serum samples with a considerable broad range HIV neutralising activity.
The verification of the neutralising activity can be carried out by using methods
and techniques known per se, which the person skilled in the art is able to apply
to the specific case without the exercise of any inventive activity and without undue
experimentation.
[0037] Preferably, the human polyclonal anti-gp120 antibodies used as the template are purified
anti-gp120 immunoglobulins G (IgG). The purification is preferably effected by (immuno)affinity
chromatography procedures, for example, by using G protein-containing sepharose columns
for IgG purification and gp120-containing columns for the purification of specifically
HIV gp120 antigen-directed antibodies.
[0038] Another preferred feature of the human polyclonal anti-gp120 antibodies used as the
template is that they are in the form of Fab fragments. Therefore, in a preferred
embodiment of the method, the purified anti-gp120 IgGs, with a broad range HIV-neutralising
activity, are provided as Fab fragments. Such anti-gp120 Fab fragments having a neutralising
activity will be further referred to as "RB1Fabs".
[0039] In the second step of the method, the RB1Fabs are used as the template for generating
anti-immunoglobulin monoclonal antibodies that are directed towards the idiotype of
the same RB1Fabs used as the template. Such anti-immunoglobulin antibodies are further
referred to as "anti-idiotype antibodies".
[0040] The expressions "directed towards" and "directed against" are used to indicate that
the antibodies at issue are able to react with, i.e. to immunologically bind to, the
indicated antigen.
[0041] As known, the Fab fragments are antibody fragments capable of binding the antigen,
obtainable by digestion of whole immunoglobulins with the papain enzyme. More particularly,
a Fab fragment consists of an intact light chain associated with a VH-Cγ1 fragment
of a heavy chain. By digestion of a whole IgG with the papain enzyme, two identical
Fab fragments are obtained.
[0042] Within the scope of the inventive method, the use of Fab fragments as the template
for generating anti-immunoglobulin monoclonal antibodies advantageously allows for
obtaining a panel of antibodies that are more specifically directed towards the useful
portion of the immunoglobulins used as the template, i.e. their idiotype. Therefore,
such antibodies are referred to as "anti-idiotypes". The term "idiotype" refers to
the totality of the hypervariable regions of the variable domain of an immunoglobulin,
which is to say those structures that characterize a homogeneous population of antibody
molecules, such as for example the proteins of a myeloma or a monoclonal antibody,
and thus allow for distinguishing between one homogeneous population of antibody molecules
and another homogeneous population (for instance, between one monoclonal antibody
and another).
[0043] Any conventional technology for the preparation of monoclonal antibodies, for example,
but without limitation, the hybridoma technique, the phage display technique, the
yeast display technique, the ribosome display technique, can be used to obtain the
panel of anti-idiotype monoclonal antibodies. Preferably, the anti-idiotype monoclonal
antibodies obtained in this step are mouse antibodies, generated by the hybridoma
technique by immunizing mice with the RB1Fabs.
[0044] Finally, in the third step of the method, the panel of anti-idiotype monoclonal antibodies
obtained in the second step is screened to select a subset of antibodies with the
ability to inhibit the binding of gp120 to human anti-gp120 antibodies, preferably
to the RB 1Fabs used as the template. This allows for ascertainment that the anti-idiotypes
obtained with the inventive method are true mimotopes, i.e. anti-idiotype antibodies
capable of immunologically mimicking the gp120 antigen. The screening can be carried
out by any suitable known method for such purpose, for example by ELISA, as described
in the following experimental section.
[0045] The scope of the invention also includes a panel of anti-idiotype monoclonal antibodies,
preferably mouse antibodies, characterized by being specifically directed against
the idiotype of human anti-gp120 antibodies and by being able to inhibit the binding
between gp120 and human anti-gp120 antibodies. Such a panel of anti-idiotype monoclonal
antibodies is obtainable by the method of the invention.
[0046] The term "panel of anti-idiotype antibodies" is used to indicate the totality of
the different populations of anti-immunoglobulin monoclonal antibodies that are generated
with the inventive preparation method. Thanks to the specific preparation method used,
the various populations of anti-immunoglobulin monoclonal antibodies obtained, although
differing from one another precisely in the structure of the antigen-binding regions,
all share a common feature, i.e. they are directed towards the idiotype of the RB1Fabs
used as the template, and thus can be defined as populations of anti-idiotype monoclonal
antibodies.
[0047] From the above explanation, it is thus evident that, within the scope of the present
description, the term "anti-immunoglobulin antibody" is not synonymous with the term
"anti-idiotype antibody". An anti-immunoglobulin antibody generically is an antibody
obtained by immunizing an animal with an immunoglobulin, which in this case acts as
the antigen. The anti-immunoglobulin antibody can be directed towards any immunoglobulin
region used as the antigen, including, for instance, the Ig constant region or other
conserved portions. Instead, an anti-idiotype antibody is an anti-immunoglobulin antibody
specifically directed towards the idiotype of the immunoglobulin used as the antigen.
Therefore, the category of the anti-idiotype antibodies is more specific than that
of the anti-immunoglobulin antibodies.
[0048] The experimental section of the present patent application illustrates in detail
the method for the preparation of the anti-idiotype monoclonal antibodies of the invention
and the immunological features that make some of the obtained antibodies particularly
effective in vaccine (therapeutic or prophylactic) applications against HIV infection
or diseases related thereto. The attainment of anti-idiotype monoclonal antibodies
in the form of Fab fragments is specifically illustrated in the experimental section.
Also, two specific anti-idiotype Fabs (designated as P1 and P2) are described, which
were obtained by molecular biology techniques starting from hybridomas, and identified
by the amino acid and nucleotide sequences of the variable portions of their heavy
and light chains. Such sequences are provided in the specification section entitled
"Sequence listing".
Obviously, the anti-idiotype antibodies of the invention, including P1 and P2, can
be prepared and used in forms other than the Fabs, for instance as whole immunoglobulins,
or else in the form of other antibody fragment types (for example F(ab')
2 fragments or antibody fragments smaller than the Fabs) or even as peptides having
the same immunological properties as the Fabs of the invention.
For example, single chain antibodies can be constructed according to the method described
in
US patent 4,946,778 by Ladner et al. Single chain antibodies comprise the light and heavy chain variable regions connected
through a flexible linker. The antibody fragment designated as single domain antibody
is even smaller than the single chain antibody, as it is comprised of a single isolated
VH domain. Techniques for obtaining single domain antibodies having at least in part
the same binding ability as the whole antibody are known in the prior art. For example,
Ward, et al., in "Binding Activities of a Repertoire of Single Immunoglobulin Variable
Domains Secreted from Escheria coli," Nature 341:644-646, describe a screening method for attaining the variable region of an antibody's heavy
chain
(VH single domain antibody) with sufficient affinity to the target epitope so that it will bind to it in an isolated
form.
In the following description, the term "anti-idiotype antibody" will therefore be
used to refer to all the above mentioned anti-idiotype antibody embodiments, i.e.
whole immunoglobulins, Fab fragments or other antibody fragment types, single chain
antibodies, single domain antibodies, etc.
[0049] The anti-idiotype antibodies of the invention can be generated and used in a free
form or in a carrier-conjugated form. A carrier is any molecule capable of conjugating
with an antibody and making it immunogenic or increasing its immunogenicity.
[0050] Non-limiting examples of carriers are proteins such as KLH (keyhole limpet hemocyanin),
edestin, thyroglobulin, albumins such as bovine serum albumin (BSA) or human serum
albumin (HSA), erythrocytes such as sheep erythrocytes (SRBC), tetanus anatoxin, cholera
anatoxin, polyamino acids such as poly(D-lysine:D-glutamic acid) and the like. In
order to facilitate the binding of the anti-idiotype to the carrier, the anti-idiotype
C-terminus or N-terminus may be modified, for example, by insertion of additional
amino acid residues, for instance one or more cysteine residues that are able to form
disulfide bridges.
[0051] Because of their properties, which will be shown in detail in the experimental section,
the anti-idiotype antibodies of the invention are particularly suited for use in therapeutic
and/or diagnostic applications, particularly in the manufacture of a medicament for
the prophylactic or therapeutic treatment of HIV infection or diseases related thereto,
and in methods for the detection of anti-HIV gp120 antibodies in biological samples.
[0052] Also disclosed are the amino acid and nucleotide sequences of the heavy and light
chain variable regions of two specific anti-idiotype Fabs of the invention, designated
as P1 and P2 respectively. As described in detail in the experimental section, the
P1 and P2 Fabs have been obtained by means of molecular biology techniques starting
from two hybridomas, designated as Mab1 and Mab2, which were able to produce anti-idiotype
monoclonal antibodies capable of inhibiting the immunologic binding between gp120
and the RB1Fabs. The exact procedures used to generate the P1 and P2 Fabs of the invention
are disclosed in detail in the experimental section. In general terms, the mRNA of
the genes encoding for the light and heavy chain variable regions of the monoclonal
produced by the Mab1 hybridoma was cloned into an expression vector known per se,
designated as RBCaf, and the recombinant construct thus obtained was transformed into
E. coli strain XL1Blue cells that had been made competent. The same procedure was applied
to the monoclonal antibody produced by the Mab2 hybridoma. About 40 recombinant bacterium
clones were obtained for each monoclonal antibody. The recombinant bacterium clones
were then selected according to their ability to generate mouse Fabs capable of binding
the purified RB1Fabs. Two clones were selected in this way, one for each monoclonal,
designated as Pomona1 (P1) and Pomona2 (P2), respectively. The amino acid and nucleotide
sequences of the heavy and light chain variable regions of the mouse P1 and P2 Fabs
have been obtained. Such sequences are reported in the section entitled "Sequence
listing".
[0053] The mouse P1 and P2 Fabs resulted as advantageously positive, not only for their
ability to inhibit the gp120-RB1Fab binding, but also for their ability to stimulate
a specific anti-gp120 immune response in animal models other than mice, for instance
in rabbits. The immunisation experiments described in the experimental section of
the patent application show that these Fabs are able to evoke a rapid and strong specific
anti-gp120 immune response, also evident at high serum dilutions (1:1600). It has
also been possible to verify that the anti-gp120 antibodies evoked in rabbit in response
to immunisation with the P1 and P2 Fabs of the invention display a high HIV-neutralising
ability. The obtained data indicate that the P1 and P2 molecules of the invention
are particularly useful in vaccine applications, especially for the prophylactic and
therapeutic treatment of HIV infection or diseases related thereto.
[0054] Not only are such properties predicted on the basis of the observation that the ability
of the inventive antibodies to evoke a robust antiviral immune response (without using
the virus) has been ascertained in an animal model phylogenetically very distant from
man, such as the rabbit, but they have also been experimentally verified by neutralising
activity evaluation assays of sera from rabbits immunized with the anti-idiotype monoclonal
antibodies of the invention. The results of such neutralisation experiments, which
have been performed using a human glyoma cell line, are illustrated in the following
experimental section.
[0055] Thus, an immunogenic composition comprising an immunologically effective amount of
at least one anti-idiotype antibody of the invention (preferably a P1 or P2 molecule)
and a pharmaceutically acceptable carrier and/or diluent is also included in the scope
of the invention. An immunologically effective amount of at least one anti-idiotype
antibody of the invention is an amount that is able to induce an anti-gp120 immune
response in an animal host to which it is administered, including a human being.
[0056] Optionally, the immunogenic composition can further comprise one or more adjuvants.
An adjuvant is a compound having a non-specific stimulation activity on the immune
system. Non-limiting examples of adjuvants are complete Freund's adjuvant, incomplete
Freund's adjuvant, vitamin E, non-ionic block polymers, muramyl peptides, immunostimulant
complexes, saponins, mineral oils, vegetable oils, Carbopol, thermolable
E. coli toxin (LT), cholera toxin (CT), aluminium hydroxide, aluminium phosphate or aluminium
oxide, etc.
[0057] Other non-limiting examples of useful pharmaceutically acceptable carriers or diluents
for the immunogenic composition of the invention include stabilizers such as SPGA,
carbohydrates (for example, sorbitol, mannitol, starch, sucrose, glucose, dextran),
proteins such as albumin or casein, protein-containing agents such as bovine serum
or skimmed milk, and buffers (for example phosphate buffer).
[0058] As will be described in detail in the following experimental section, it has been
ascertained that the results achievable by immunization of test animals (for example,
rabbits) with the anti-idiotype molecules of the invention can be further improved
(in terms of the anti-gp120 immune response intensity, see figure 3) by subjecting
the animals to a particular immunization regime, which contemplates the simultaneous,
separate or sequential administration of the anti-idiotype antibodies of the invention
(preferably P1 or P2) and the gp120 antigen or other naturally occurring or artificial
antigens.
[0059] Therefore, a kit of parts comprising an anti-idiotype antibody of the invention,
preferably P1 or P2, and the HIV gp120 antigen or other naturally occurring or artificial
antigens, as a combined preparation for the simultaneous, separate or sequential administration
in a therapeutic or prophylactic immunization regime against HIV, is also included
in the scope of the present invention.
[0060] Finally, given their proven ability to specifically react with anti-HIV gp120 antibodies,
the anti-idiotype antibodies of the invention, preferably P1 and P2, can be used as
diagnostic reagents in an
in vitro method for detection of anti-gp120 antibodies and/or antibody subpopulations in a
biological sample, such as for example a sample of serum, plasma, blood or any other
suitable biological material derived from an animal, including a human being, for
example a patient infected or suspected of being infected by HIV.
EXPERIMENTAL SECTION
Obtaining human IgGs from HIV virus-neutralising sera
[0061] Human IgGs were purified from sera of HIV-positive patients clinically characterized
by a slow progression of the disease (long-term non-progressors).
[0062] These patients were chosen by following the most stringent clinical-virological criteria
in the definition of long-term non-progressors. All the selected patients in fact
were characterized by the following parameters:
- HIV-seropositive for at least 8 years;
- CD4+ T lymphocyte levels exceeding 600 cells/µl for at least 5 years (this is an extremely
important parameter for the evaluation of the chosen subjects' immunological status,
not only at the time of the study, but also during a long period of time before the
study);
- no HIV-related clinical signs for at least 5 years (this is an extremely important
indication of control of infection over time).
[0063] By following these parameters it has been possible to obtain over time (with obvious
difficulties given the strictness of the proposed criteria) serum samples with a surprisingly
broad range neutralising activity, and thus optimal for the continuation of the study.
[0064] Furthermore, not all of the selected patients' serum samples have been used as the
polyclonal preparation template to obtain anti-idiotypes: only sera capable of significantly
inhibiting a broad panel of HIV isolates have been chosen for the continuation of
the study.
[0065] Serum aliquots from these patients were assessed for their HIV-1-neutralising ability.
[0066] Briefly, for the virus neutralisation, a reference lymphotropic virus strain (HIV-1
IIIB) (Advanced Biotechnologies Inc. - ABI) was first titrated by
Karber's method (Oxford University Press, Virus Culture - A Practical Approach, ed.
A.J. Cann, p. 84) on a HTLV-1-transformed human cell line (C8166 - ECACC # 88051601), using 6 replicas
for each virus dilution (range: 1:10 to 1:16000), thereby obtaining a virus titre
expressed as TCID
50 (i.e. the dose capable of determining a cytopathic effect in 50% of the infected
cells). In the neutralisation tests, 100 TCID
50 were thus preincubated with stepwise dilutions of the chosen sera, assessing the
ability of the latter to inhibit C8166 cell infection by the virus. To that end, culture
supernatants were taken at days 3, 7 and 10 post-preincubation in order to measure
the viral p24 (Vidas
® HIV Duo Ultra, Biomerieux).
[0067] Sera with higher neutralising activities were selected, and all of the aliquots were
combined. Purification of the IgGs from serum was carried out by immunoaffinity chromatography.
In short, the pool of neutralising sera was diluted with 3 volumes of PBS (phosphate
buffered saline: NaCl 8 mg/ml; KCl 0.2 mg/ml; Na
2HPO
4 1.44 mg/ml; KH
2PO
4 0.24 mg/ml) and filtered through 0.45 µm filters (Millipore Corporation; Bedford,
MA). The filtrate was then passed through a protein G-containing sepharose column
(Gammabind Sepharose™, GE Healthcare Life Sciences, UK). Subsequent to one washing
of the column with 10 volumes of PBS, the bound IgG component was eluted with 10 volumes
of 0.1 M citric acid, pH 3, and quickly neutralised with a basic solution (1.5 M Tris-Base).
The various obtained fractions were then read in a spectrophotometer (O.D. 280 nm)
in order to assess the amount of IgG obtained.
Purification of anti-HIV gp120 antibodies
[0068] Antibodies directed against HIV gp120 glycoprotein were purified by modifications
of a technique already described (Hariharan et al, 1993). Briefly, 700 µg of a recombinant
type IIIB gp120 glycoprotein (ImmunoDiagnostics Inc., Woburn, MA) were coupled through
covalent binding to CNBr-activated Sepharose 4B (CNBr-activated Sepharose™ 4B, GE
Healthcare Life Sciences, UK). The aforesaid amount of antigen dissolved into 4 ml
of coupling buffer (100mM NaHCO
3; 500 mM NaCl; adjusted to pH 8.2 with HCl) was added to 4 ml of 50%-reconstituted
resin, after a washing with 1mM HCl. The mixture was subjected to rotary mixing overnight
at 4°C, and the excess non-bound antigen was washed with an excess of coupling buffer.
The resin was then transferred into a 10 ml syringe and washed with ten volumes of
10mM Tris, pH 7.5. 10 volumes of 100mM glycine (pH 2.5) were then applied to the column,
followed by 10 volumes of 10mM Tris (pH 8.8) and 10 volumes of 100mM triethylamine
(pH 11.2), and finally the column was washed with 10mM Tris (pH 7.5) until the pH
reached 7.5.
[0069] The patients' antibodies, diluted 1:3 into 10mM Tris (pH 7.5), were slowly passed
7 times onto the resin-containing column at 4°C. The column was then washed with 10
volumes of 10mM Tris (pH 7.5) and the antibodies were finally eluted with 100mM glycine
(pH 2.5), and immediately neutralised. The fractions were analysed for their reactivity
towards gp120 by ELISA. In particular, each well was coated with 100 ng of antigen
resuspended into 25 ml of PBS, and subsequently the plates were incubated overnight
at 4°C. Similarly, some wells were coated with a control antigen, bovine serum albumin
(BSA- #A7030-Sigma, St. Louis, MO). The excess antigen not bound to the plate was
then removed by a series of washings with distilled water. The plates were blocked
with PBS/1% BSA, and incubated for 1 hour at 37°C. Stepwise dilutions (from 1:100
to 1:6400) of each of the purified fractions as described were then added and allowed
to incubate with the antigens for 2 hours at 37°C. After a round of 10 washings with
PBS/0.05% Tween 20, 40 µl of a 1:700 dilution in PBS/1% BSA of a horseradish peroxidase-conjugated
goat polyclonal antibody solution (Sigma, St. Louis, MO), directed against the Fc
portion of human IgGs, were added to each well. After a 1 hour incubation at 37°C,
another 10 washes with PBS-Tween were carried out. The enzyme substrate (OPD-o-phenylenediamine
- Sigma) was then added to the wells, and the signal was detected by spectrophotometric
reading at 450 nm O.D., care being taken to compare the gp120 values with the BSA
values.
[0070] The fractions containing anti-gp120 antibodies were combined in a single preparation
and concentrated by ultrafiltration.
[0071] The absence of contaminating antibodies was demonstrated by analyzing the purified
antibodies for their reactivity towards antigens against which antibodies were present
in patients' serum before the preparation (Herpes Simplex Virus and Rubella Virus
antigens). To that end, Vero cells (ATCC # CCL-81) had been infected with the two
viruses (ATCC # VR-733; ATCC # VR-553). After a 6 day incubation at 37°C, the infected
cells (and non-infected Vero cells as a negative control) were collected. The cell
pellets were then resuspended into 250 µl of lysis buffer (50mM Tris-HCl pH 8, 150mM
NaCl; 0.02% Sodium Azide; 0.5% Triton-X), incubated for 20 minutes in ice and centrifuged
at 12000 g for 2 minutes at 4°C. The protein concentration in the supernatant was
then calculated by using a commercially available kit (BCATM Protein Assay Kit - Pierce,
Rockford, Illinois). 300 ng of protein extract were then used to coat ELISA plate
wells, according to the protocol previously described for gp120.
Production of Fab fragments
[0072] Fab fragments from the purified anti-gp120 IgGs were produced by using the Pierce
ImmunoPure Fab Preparation Kit (Pierce, Rockford, IL) according to the instructions
provided by the manufacturer. The human Fabs obtained by this experiment (designated
as RB1Fabs) were used to immunize mice and for some ELISA assays described further
below.
Production of mouse anti-idiotype monoclonal antibodies (mAbs)
[0073] Female 4-6 weeks old Balb/c mice (Charles River Corporate, Wilmington, MA) were immunized
by a weekly intraperitoneal injection repeated three times with 0.5 ml PBS containing
about 50 µg purified human Fabs (RB1Fabs), together with an equal volume of incomplete
Freund's adjuvant (Gibco). These 3 administrations were followed by another 3, again
weekly via the intraperitoneal route, but without the incomplete adjuvant. Before
the start of the protocol, and after this immunization schedule, blood was drawn and
each animal's antibody response to Fabs derived from purified IgGs of HIV-seronegative
patients' sera was assessed by ELISA. Briefly, the assay was carried out as described
for the previous ELISAs, by coating the wells with 300 ng of Fabs. Stepwise dilutions
(from 1:100 to 1:6400) were then prepared from each animal's pre-immune serum and
from the serum drawn after the immunization protocol. Mouse antibodies bound to the
different preparations were then detected by a polyclonal preparation of goat antibodies
(Sigma, St. Louis, MO) directed against the Fc portion of the mouse antibodies. In
the event of a satisfying response (O.D. 450 of the immune serum 1:1600 dilution at
least >1.5 over the value obtained with the pre-immune serum), a final antigen inoculation
was then carried out 3 days before the sacrifice of the animals for the fusion.
Production of mouse monoclonal antibodies
[0074] Production of mouse monoclonal antibodies was carried out by using the already described
methodology (R.Burioni, doctoral thesis, 1993) with a few modifications.
[0075] Briefly, cells derived from a mouse NS-1 myeloma cell line (ECACC # 85011427) were
used as the fusion partner. The cells as well as the hybridomas originated from them
were cultured in RPMI-1640 medium (Gibco) supplemented with 20% complement-inactivated
bovine fetal serum (Flow). Two media were used for the fusion. The first one, called
fusion medium, was prepared with 5 ml of EMEM medium (Invitrogen), 0.75 ml of Dimethylsulfoxide
and 4.75 ml of PEG1540. Instead, HAT and HT selective media were prepared with 375.5
ml of RPMI-1640 medium, 100 ml of complement-inactivated bovine fetal serum, 13.5
ml of 7% sodium bicarbonate, and 5 ml of a 100x HAT solution (Ipoxantine 1.36 mg/ml,
Thymidine 0.388 mg/ml, Aminopterin - not present in the HT medium - 0.019 mg/ml).
Penicillin (100 mIU/ml), Streptomycin (100 µg/ml), L-glutamine (2 mM final concentration)
and Amphotericin B (100µg/ml) were also added to the media.
[0076] Three days after the last inoculation contemplated by the immunization schedule,
the mice were killed by cervical dislocation and their spleens were removed in sterile
conditions. The spleen was washed and reduced to pieces by using syringe needles.
Spleen cells were then separated from the connective fibrous septa allowing the latter
to sediment in a test tube for a few minutes under the same sterile hood. The spleen
cells were resuspended into EMEM medium, washed by centrifugation (1500 rpm for 10')
and resuspended into EMEM medium supplemented with penicillin and streptomycin.
[0077] Simultaneously, NS-1 myeloma cells were grown for 2 days in culture starting from
an initial inoculum of approximately 500,000 cells. The cells were then washed in
EMEM medium by centrifugation (1500 rpm for 10') and again resuspended into EMEM supplemented
with penicillin and streptomycin.
[0078] The two cell pellets (one composed of spleen cells, the other of myeloma cells obtained
through culture) were finally resuspended into 10 ml of EMEM medium, combined into
a single test tube, and centrifuged for 10' at 1500 rpm, obtaining a pellet composed
both of spleen cells and myeloma cell lines.
[0079] Immediately, within 1 minute, the cells were gently resuspended into 1 ml of fusion
medium, to which 5 ml of EMEM medium were added over the following 3 minutes. During
the subsequent 3 minutes, 7 ml of RPMI medium containing 20% complement-inhibited
bovine fetal serum were added. The cells were centrifuged (1200 rpm for 15') and the
pellet resuspended into 10 ml of HAT medium, to be then diluted into 200 ml of the
same medium. After a 1 hour incubation at 36.5°C in a controlled atmosphere room containing
5% CO
2, the cell suspension was dispensed into 10 96-well Microtiter plates (NUNC), 200
µl for each well, and incubated in the same room described above.
[0080] The plates containing the cells derived from the fusion were observed during the
subsequent days to assess for a possible growth of hybridomas. In case of growth,
the cell culture supernatant was evaluated for the presence of antibodies by ELISA.
The hybridomas were then cloned by limiting dilution, expanded and, in part, maintained
in liquid nitrogen.
[0081] Clones that by ELISA (following the described protocol) demonstrated a reactivity
against Fab preparations obtained from HIV-seronegative patients' sera were immediately
discarded. Clones that proved negative towards the preparations obtained from the
seronegative patients' sera were assayed for their reactivity to the anti-gp120 IgG
preparations purified from the seropositive patients. Clones positive for such reactivity
were assayed in ELISA by using as the antigen the Fab fragments thereof, and employed
in the immunization of mice (RB1Fabs). Mouse monoclonal antibodies capable of reacting
against the latter preparation (RB1Fabs) were purified by using Montage PROSEP-A columns
(Fisher) according to the manufacturer's directions. Finally, the purified and concentrated
antibodies were evaluated for their ability to inhibit the binding of the anti-gp120-purified
Fabs derived from the patients' serum (RB1Fabs) to the antigen itself (gp120) in an
inhibition ELISA experiment, by modifying for mouse antibodies methods already described
(
Bugli et al, J. Virol. 2001), that is to say by using a preparation of peroxidase-conjugated goat polyclonal
antibodies specifically directed towards the mouse Fab's conserved regions (Sigma,
St. Louis, MO).
[0082] Two of the antibody clones that reacted against the purified human Fabs (RB1Fabs)
were identified as also being able to inhibit the binding between purified Fabs (RB1Fabs)
and gp120. Such clones were designated as Mab1 and Mab2.
[0083] For the preparation of the Fab fragments from the cultured cells, mRNA was extracted,
cDNAs encoding for the light chain and the heavy chain portion that is a part of the
Fab were amplified by described methods (CSH press, Phage display manual, ed. D.R.Burton,
p. A1.10), and these cDNAs were then cloned together into an already described expression
vector called RBCaf (
Burioni et al, J. Imm. Meth, 1988). Briefly, the gene (amplified DNA) encoding for the heavy chain of each Fab was
digested with the restriction enzymes
XhoI and
SpeI (Roche) for 1.5 hours at 37°C and subsequently ligated into the cloning site of the
vector for the heavy chains, digested in turn with the same enzymes. Instead, the
light chains (amplified DNA) were digested with the enzymes
SacI and
XbaI (Roche) and then cloned into the similarly digested vector.
[0084] The recombinant constructs thus obtained for each of the 2 clones were then used
to electro-transform
E.coli XL1Blue strain (made competent through cold washes in glycerol), according to standardized
protocols for the usage of 0.2 cm cuvettes (Voltage: 2500 V; Capacitance: 25 µF; Resistance:
200 Ω).
ELISA evaluation of monoclonal Fabs obtained through cloning into RBCaf
[0085] Bacterium clones transformed with the RBCaf construct were inoculated into 10 ml
of SB medium containing ampicillin and tetracycline at 50µg/ml and 10µg/ml respectively,
and grown with shaking at 37°C until reaching an O.D.600 = 1. Successively, a specific
inductor (IPTG-isopropylβ-D-thiogalactopyranoside) was added at 1mM final concentration,
and the culture was kept shaking at 30°C overnight. The cells were lysed by heat-shock
(3 rounds of freezing-thawing at -80°C and 37°C, respectively) and then centrifuged
in order to separate the cell debris from the Fab-containing supernatant. The obtained
soluble Fabs were assayed by ELISA. 96-well Microtiter plates (Nunc) were coated with
the RB1 purified Fabs (300 ng per well) and BSA as the negative control antigen, and
incubated overnight at 4°C. After removing the non-bound antigen, the plate was washed
5 times with PBS, and the non-specific binding sites were blocked with 3% albumin
in PBS for 1 hour at 37°C. After removing the blocking solution, the cell culture
supernatants treated as above and containing the soluble Fabs were added. This was
followed by an incubation step at 37°C for 2 hours. After a round of 10 washes with
PBS/0.05% Tween 20, 40 µl of a 1:700 dilution in PBS/1% BSA of a polyclonal preparation
of horseradish peroxidase-conjugated goat immunoglobulins (Sigma), directed against
mouse Fabs, were added. After a 1 hour incubation at 37°C and a further series of
10 washes, the substrate (OPD-o-phenylenediamine) was added to the wells. The plates
were then incubated for 30 minutes at room temperature in the dark. The reaction was
stopped with 1N sulphuric acid and the optical density was assessed by spectrophotometric
reading at 450nm.
[0086] At the end of the cloning, 40 recombinant bacterium clones were analyzed for each
monoclonal antibody as just described and, for each of them, a clone capable of generating
mouse Fabs able to bind the purified human Fabs (RB1Fabs) was selected. Successively,
the light chain variable portion and heavy chain variable portion DNA sequences of
these selected clones, designated as Pomona1 and Pomona2 (P1 and P2), were analyzed.
Such sequences are those provided in the Sequence listing section.
Purification of the P1 and P2 Fabs
[0087] The P1 and P2 Fabs were then immunoaffinity purified, through columns filled with
a G protein-containing (~ 2 mg/ml) sepharose resin, to which a polyclonal preparation
of goat anti-mouse Fab antibodies (PIERCE, Illinois) was covalently bound. Briefly,
a colony of each clone was inoculated into 10 ml of SB medium containing ampicillin
and tetracycline at 50µg/ml and 10µg/ml, respectively. The culture, grown overnight
at 37°C, was subinoculated into a flask with 500 ml of SB supplemented with the same
concentration of antibiotics as before. The cells, subsequently induced with 1mM IPTG,
were kept shaking overnight at 30°C. The culture was centrifuged at 5000 rpm for 25
minutes and the pellet resuspended in PBS was sonicated. A subsequent centrifugation
at 18,000 rpm for 25 minutes was needed to remove the cell debris and the supernatant
was filtered and then slowly passed through the sepharose column as previously described.
Then, the resin was washed with 10 volumes of PBS and finally the bound Fabs were
eluted with an acid solution (elution buffer - H
2O/HCl pH 2.2) and the collected fractions were neutralised with the proper solution
(Tris 1M pH 9). The collected fractions were concentrated by ultrafiltration (Centricon,
Millipore). The purity of the purified fraction was assessed by running an aliquot
on a 12% sodium dodecyl sulphate/polyacrylamide gel (SDS-PAGE). Eventually, stepwise
dilutions of such purified Fabs were assayed by ELISA as previously described. Monoclonal
Fab preparations directed against the HCV E2 glycoprotein (
e8; e20; e137; e509; Burioni et al, Hepatology, 1998) were included in each plate as negative controls.
[0088] The obtained results are disclosed in figure 1, wherein the mean optical density
values (with their relative standard deviations) related to the monoclonal P1 and
P2 Fabs are reported. All reported data were generated by ELISA experiments performed
in 3 different sessions wherein each dilution point was repeated in duplicate.
[0089] These data show a high reactivity of both P1 and P2 Fabs towards the FabRB1 preparation,
moreover such Fabs are not able to bind the panel of human Fabs characterized by a
different binding specificity to FabRB1. Even at the highest concentration (~ 30 µg/ml)
the two mouse Fabs, in fact, are not able to recognize the Fab preparations with different
binding specificities; in fact, in all the experiments the O.D. 450 values resulted
to be 0.5 or less, with respect to the higher than 2.5 values detected with the RB1
preparation. Furthermore, both the Fabs proved to be able to recognize the RB1 preparation
even at the lowest concentration (∼ 0.5 µg/ml) used in the experiments.
Evaluation of the ability of the obtained anti-idiotype molecules to stimulate a specific
anti-gp120 response in animal models
[0090] The P1 and P2 molecules, obtained as described above, were used to immunize animal
models other than mice, in order to assess their ability to stimulate a specific anti-HIV/gp120
response. Particularly, female 4-5 week old New Zealand rabbits (Allevamento Bettinardi,
Novara, Italy), weighing between 2.3 and 2.5 kg, were used. The animals (6 per group)
were divided into three cohorts:
- A cohort: animals immunized with the anti-P1 idiotype Fab;
- B cohort: animals immunized with the anti-P2 idiotype Fab;
- C cohort: animals immunized with a control Fab (JO1) devoid of anti-idiotype features.
[0091] Two weeks before the beginning of the immunization protocol, up to a maximum of 5
ml of blood was drawn from each animal's ear medium artery in order to obtain pre-immune
sera. 200 µg of each antigen, resuspended into 500 µl max. of physiological solution
and 500 µl of adjuvant solution, were then administered at three week intervals by
multiple injections (max. 10) on the back, after appropriate antiseptic preparation
of the inoculum site. The purity of each immunoaffinity-purified antigen was assessed
by SDS-PAGE. Moreover, prior to the emulsion with the adjuvant, each antigen solution
was first filtrated through 0.2 µm filters. 2 weeks after the third immunization,
a maximum of 5 ml of blood was drawn from each animal in order to evaluate the humoral
response by ELISA. With an approach analogous to those disclosed in the previous paragraphs,
ELISA plates were coated with 50 ng/well of gp120 (HIV IIIB) and kept overnight at
4°C. The following day, the unbound antigen was removed by washing with a physiological
solution. The non-specific sites of each well were then blocked with a PBS/1% BSA
solution, keeping the plates in incubation for 1 h at 37°C. Stepwise dilutions of
the pre-immune and post-immune (after 3 immunizations) sera from each animal were
then added to the wells and incubated for 1.5 hours at 37°C. The plates were then
washed automatically 5 times with a PBS/0.05% Tween 20 solution, and the antibodies
bound to the antigen were then detected with a suitable dilution of a horseradish
peroxidase-conjugated anti-rabbit Ig polyclonal (Pierce). After a further hour incubation
at 37°C, and another subsequent 5 washings, the obtained signal was read as previously
described.
[0092] The obtained results are disclosed in figure 2, wherein the mean values (with their
relevant standard deviations) of the anti-gp120 response stimulated into rabbits belonging
to the 3 different immunization groups are reported. The reported data are related
to ELISA experiments repeated in duplicate in three different sessions for each dilution
point.
[0093] From this series of data it is evident that both the antibodies are able to evoke
an anti-gp120 immune response in experimental animals, thereby turning out to be potentially
useful molecules in vaccine applications. The response is also evident at high serum
dilutions (1:1600), with a mean O.D. 450 nm increase above 1 in the case of animals
immunized with P1, and of about 0.5 in the case of P2. The comparison between the
data obtained from the cohorts immunized with the anti-idiotypes and those obtained
from the cohort immunized with the mouse control antibody (JO-1) also allowed for
verification of the statistical validity of the results. In particular, by applying
a non-parametric test for nonpaired data (Mann - Whitney test) to the study, it has
been possible to demonstrate that the distribution of the results obtained from the
3 animal groups is not at all accidental, as evidenced by the p values below 0.05
in each case. Moreover, the significance increases at the highest serum dilutions
(1/800 and 1/1600), with p values below 0.01. Besides confirming the statistical validity
of this experiment conducted on a minimal number of animals, the latter data testify
the specificity of the observed phenomenon.
Immunization with gp120 of rabbits previously immunized with monoclonal anti-idiotype
antibodies
[0094] Six weeks after the second boost with P1, P2, and JO1, rabbits respectively belonging
to the A, B, and C cohorts were immunized with gp120. 200 µg of antigen resuspended
into 500 µl of physiological solution and 500 µl of incomplete Freund's adjuvant (Gibco)
were administered according to the same mode as previously described. Two weeks after
the immunization, about 5 ml of blood were drawn from each animal in order to evaluate
the anti-gp120 humoral response by ELISA, with an approach analogous to that previously
described. The data were obtained by ELISA experiments repeated in duplicate for each
dilution point and in three different sessions.
[0095] The data presented in figure 3, wherein the mean values (with their relevant standard
deviations) of the anti-gp120 response stimulated into rabbits belonging to the 3
different immunization groups are reported, show that the 3 rabbit groups responded
to gp120 after the first immunization and also point out the presence of a greater
response in the rabbit cohorts immunized with P1 and P2 compared to the rabbit cohort
immunized with JO1. These data indicate that animals exposed to P1 and P2 are able
to mount a more effective immune response to gp120 compared to those exposed to a
control antigen.
Evaluation of the neutralising activity of sera from rabbits immunized with the monoclonal
anti-idiotype antibodies
[0096] The neutralisation experiment was performed by using U87.CD4 cells (CXCR4) (NIH AIDS
Research &
Reagent Program), an adherent-growing human glyoma cell line that expresses the CXCR4 co-receptor on
its surface. The high glucose DMEM with Napyruvate and L-glutamine (EuroClone), supplemented
with 300 µg/ml G418 (GIBCO), 1 µg/ml puromycin (Sigma), and 10% complement-inactivated
bovine fetal serum (EuroClone), was used as the culture medium to maintain the cell
line. The neutralising activity of the pre-immune serum, and of the serum collected
after three immunizations with the anti-idiotype molecules (P1 and P2) or with the
control antibody (JO1) was assessed for each animal. The BH8 isolate (GenBank #
K02011), a virus belonging to the IIIB subtype, was used as the HIV-1 isolate.
[0097] First of all, the aforesaid cells were transferred to a 96-well microtiter plate
(Costar), in order to have about 8 x 10
3 cells in each well. The next day, sterile transfer plates (Costar) were prepared
wherein the virus was incubated with the sera to be tested. In particular, the culture
medium containing the virus at a final load of 100 TCID
50, and a 1/10 final dilution of each serum, after complement-inhibition at 56°C for
30 minutes, were added to each well. A human polyclonal preparation derived from HIV-positive
patients, which was known to be able to neutralise the HIV-1 isolate in question,
was used as the positive control for the experiment. Instead, a preparation of standard
immunoglobulins was used as the negative control. Each single point was repeated in
triplicate, and kept in incubation in the transfer plates for 1 hour at 37°C in a
5% CO
2 atmosphere. Thereafter, 100 µl of the solution containing the virus and the serum
were transferred from the transfer plate to the infection plate that contained the
cells, and kept in incubation overnight again at 37°C in a 5% CO
2 atmosphere. In addition, a positive control for the infection, only containing cells
and viruses (100 TCID
50), a control for the cell viability only containing cells, and a control for the toxicity
only containing cells and serum, were inserted to complete the experiment and treated
as described.
[0098] The following day, the infection plate was washed twice with sterile PBS, and 100
µl of the same culture medium as previously described were added to each well. The
cells treated this way were then kept for six days at 37°C in a 5% CO
2 atmosphere. At the end of the six days, the p24 produced was measured in the supernatant
of each well with a commercial kit (Abbott AXSYM). The mean and the variability coefficient
of the obtained p24 values were calculated for each serum tested in triplicate, which
were then compared to the values obtained in the wells containing the infection positive
control, tested in quintuplicate. This way it has been possible to evaluate the neutralising
activity of each serum, expressed as the percentage of the decrease in the obtained
p24 values compared to the control.
[0099] None of the pre-immune sera showed a neutralising activity, consistent with the data
obtained on the sera collected after the immunizations with the mouse antibodies.
Particularly, only the sera of animals immunized with the anti-idiotype molecules
resulted in a decrease of the p24 measured levels. As for the P1 group, in fact, 3
out of 6 animals displayed a neutralising activity towards the HIV-1 isolate used,
with percentages varying from a minimum of 31.5% to a maximum of 82.2%. Similar data
were also obtained for two rabbits immunized with the P2 anti-idiotype, with neutralising
values around 30%. The extent of the neutralising response and its presence in a considerable
number of experimental animals makes it possible to hypothesize a profitable use of
these molecules in diagnostic, and prophylactic and therapeutic vaccine practices.
In confirmation of the specificity of the obtained results, it is important to note
that, besides the aforementioned absence of neutralising activity in the pre-immune
sera, none of the sera from animals immunized with the JO-1 control antibody showed
a neutralising activity. The results obtained for each animal are summarized in the
following table. The variability seen among the immunization % of animals immunized
with the same antigen (P1 or P2) must not be surprising: it is simply due to the fact
that each individual animal responds differently to the immunization.
| ANTIGEN |
ANIMAL |
% NEUTRALISATION BH8 |
| |
1 |
82.2 |
| |
14 |
63.3 |
| P1 |
3 |
0 |
| 8 |
0 |
| |
9 |
0 |
| |
12 |
31.5 |
| P2 |
17 |
0 |
| 18 |
0 |
| 15 |
28 |
| 20 |
0 |
| 21 |
0 |
| 24 |
29.3 |
| JO1 |
10 |
0 |
| 16 |
0 |
| 4 |
0 |
| 7 |
0 |
| 5 |
0 |
| 22 |
0 |
Animals nos. 1, 14, 3, 8, 9, 12: immunized with P1
Animals nos. 17, 18, 15, 20, 21, 24: immunized with P2
Animals nos. 10, 16, 4, 7, 5, 22: immunized with JO1 |
REFERENCES
SEQUENCE LISTING
[0101]
<110> POMONA BIOTECHNOLOGIES LLC
<120> Anti-idiotype monoclonal antibodies as mimotopes of the HIV gp120 antigen
<130> PC781EC
<160> 8
<170> PatentIn version 3.3
<210> 1
<211> 129
<212> PRT
<213> Mus musculus
<400> 1

<210> 2
<211> 102
<212> PRT
<213> Mus musculus
<400> 2


<210> 3
<211> 131
<212> PRT
<213> Mus musculus
<400> 3

<210> 4
<211> 103
<212> PRT
<213> Mus musculus
<400> 4

<210> 5
<211> 387
<212> DNA
<213> Mus musculus
<400> 5

<210> 6
<211> 306
<212> DNA
<213> Mus musculus
<400> 6

<210> 7
<211> 393
<212> DNA
<213> Mus musculus
<400> 7

<210> 8
<211> 309
<212> DNA
<213> Mus musculus
<400> 8
